Press release content from PR Newswire. The AP news staff was not involved in its creation.
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
January 7, 2021 GMT
SHANGHAI, Jan. 7, 2021 /PRNewswire/ VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world’s leading treatment methods and drugs into the China market and hoping to provide more Chinese patients quick access to the world’s most advanced and reliable treatment solutions, today announced that the China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has approved the IND application to conduct a phase 2 clinical trial of TransCon TM C-Type Natriuretic Peptide (CNP) for patients with achondroplasia (ACH). The trial is ready to be launched in China as “the ACcomplisH China trial”, in coordination with the ACcomplisH trial, an ongoing ph
Share this article
Share this article
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners USA, also participated in the first closing. While the complement system has historically been difficult to target given its complexity, we believe our LOGIC drug discovery platform enables us to approach complement mediation in new and different ways, unlocking transformative therapies for patients, said Frederick Beddingfield, MD, PhD, Chief Executive Officer of Kira Pharmaceuticals. We are honored to have the support of top-tier global invest
Serán Bioscience Announces Investment by Vivo Capital
A majority investment by Vivo Capital, a healthcare investment firm headquartered in Silicon Valley, will fund the expansion of Serán s service offering, the doubling of clean room capacity by year-end, and the development and construction a new commercial scale cGMP manufacturing facility by the end of 2022.
News provided by
Share this article
Share this article
BEND, Ore., Jan. 6, 2021 /PRNewswire/ Serán Bioscience today announced that healthcare investment firm Vivo Capital has made a majority investment in Serán alongside Serán s founders who will continue to lead the Company.
Founded in 2016, Serán is a leading contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. Serán s deep experience and expertise in materials science, formulation development, engineering, and phar
Provivi Team
Successfully introducing insect pheromones to control damaging pests, the increased funding will strengthen the capacity for a global roll-out SANTA MONICA, CA, UNITED STATES, December 22, 2020 /EINPresswire.com/ Provivi, Inc. ( Provivi ), an emerging crop protection company using pheromones to protect large acreage row crops from major damaging insects, is pleased to inform the completion of a $45.5M financing round. Vivo Capital, a Palo Alto based investment fund, led the round. Returning shareholders, including Kairos Ventures, Temasek, Pontifax AgTech, Tybourne Capital, Lanx Capital, and Spruce Capital, also participated in the financing. The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico, said Dr. Pedro Coelho, Co-Founder and CEO of Provivi.
Is ARWR A Good Stock To Buy Now According To Hedge Funds?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive review of these public filings is finally over, so this article is set to reveal the smart money sentiment towards Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR).
Is ARWR a good stock to buy now? Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shareholders have witnessed an increase in hedge fund sentiment in recent months. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) was in 22 hedge funds’ portfolios at the end of the third quarter of 2020. The all time high for this statistic is 26. There were 21 hedge funds in our database with ARWR holdings at the end of June. Our calculations als